EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company’s pharmacovigilance database

Jan Endrikat iD, Alexander Ullmann iD, Christoph Gerlinger iD, Aasia Bhatti iD, Philipp Lengsfeld iD, Alexander Michel

British Journal of Radiology · 01.12.2024 · 97 (1164) · 2004-2014

DOI: 10.1093/bjr/tqae190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 23.09.2024. Verfasst von Jan Endrikat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiology R&D, Bayer AG, 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Pharmacovigilance, Contrast Media, Drug Hypersensitivity, Iohexol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyse the potential impact of patients’ sex, race, and region/country on the risk of hypersensitivity reactions after intra-venous or intra-arterial administration of iopromide.

Methods

Two analyses were performed. (1) The “Phase-IV-Analysis” evaluated an integrated pooled database of 4 non-interventional studies. (2) The “GPV-Analysis” evaluated case reports from the company’s pharmacovigilance database. The Phase-IV-Analysis was a nested case–control analysis of patients who received an injection of iopromide 300/370 mg iodine/mL. Cases had typical/unequivocal HSRs as defined by the ACR Committee on Drugs and Contrast Media 2018. The global pharmacovigilance (GPV)-Analysis was based on HSR case reports in the company database. Exposure estimates were derived from sales/market research data.

Results

The Phase-IV-Analysis comprised 152 233 patients from 37 countries. In the full-analysis set 145 033, 59 412, and 146 649 patients were included in the sex, race, and region/country cohort, respectively. The GPV-Analysis was based on 78.72 million administrations for sex and 118.56 million administrations for region/country. No GPV exposure data by race were available. Sex: Phase-IV-Analysis: The HSR incidence was significantly higher for women (0.72%) vs men (0.55%) (P ≤ .0001). The unadjusted odds ratio (OR) was 1.3 (95% CI, 1.154-1.499), the adjusted OR was 1.156 (95% CI, 1.006-1.328) (P = .04). GPV-Analysis: Reporting rates were 0.0102% for women and 0.0075% for men (P < .0001). OR: 1.36 (95% CI, 1.3-1.43). Race: Phase-IV-Analysis: No significantly different HSR incidences for white (0.70%) and Asian (0.61%) patients (P = .3094) were detected. Region/country: Phase-IV-Analysis: The overall world HSR-incidence was 0.62%. Europe: 0.52%, Asia: 0.70%, United States: 0.75%, Germany: 0.51%, China: 0.41%, South Korea: 0.76%. GPV-Analysis: The overall world HSR-reporting rate was 0.015%, varying across regions/countries.

Conclusion

Women showed a slightly higher risk for HSRs than men. Impact of race was not found. HSR-reporting varied by region/country. Advances in knowledge Risk for HSRs was increased by female sex but not by race or region/country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceContrast MediaDrug HypersensitivityIohexolDatabases, FactualHumansMaleFemaleMiddle AgedSex FactorsCase-Control StudiesAdultAgedRacial GroupsObservational Studies as TopicRisk Factors

Stichwörter der Autor:innen

Safetyhypersensitivity reactionsiopromideraceregion/countrysex

Substanzen

Contrast MediaIohexoliopromide

Autor:innen und Institutionen

  • Radiology R&D, Bayer AG, 13353 Berlin, Germany.
  • Department of Gynecology, Obstetrics and Reproductive Medicine, University Medical School of Saarland, 66421 Homburg/Saar, Germany.
  • Statistics & Data Insights, Bayer AG, Wuppertal, 42113, Germany.
  • Benefit Risk Management Pharmacovigilance, Bayer US LLC, Whippany NJ 07981, United States.
  • Division Pharmaceuticals, Integrated Evidence Generation, Bayer Consumer Care AG, 4052 Basel, Switzerland.

ORCID-Profile: Jan Endrikat, Alexander Ullmann, Christoph Gerlinger, Aasia Bhatti, Philipp Lengsfeld

Förderung

  • Bayer AG

Zitieren

APA

Endrikat, J., Ullmann, A., Gerlinger, C., Bhatti, A., Lengsfeld, P., & Michel, A. (2024). Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company’s pharmacovigilance database. British Journal of Radiology, 97(1164), 2004-2014. https://doi.org/10.1093/bjr/tqae190

Vancouver

Endrikat J, Ullmann A, Gerlinger C, Bhatti A, Lengsfeld P, Michel A. Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company’s pharmacovigilance database. British Journal of Radiology. 2024;97(1164):2004-2014. doi:10.1093/bjr/tqae190

BibTeX
@article{Endrikat2024,
  author = {Endrikat, Jan and Ullmann, Alexander and Gerlinger, Christoph and Bhatti, Aasia and Lengsfeld, Philipp and Michel, Alexander},
  title = {Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company’s pharmacovigilance database},
  journal = {British Journal of Radiology},
  year = {2024},
  volume = {97},
  number = {1164},
  pages = {2004--2014},
  doi = {10.1093/bjr/tqae190}
}
Kostenlos starten →